Compare · CTSO vs MMM
CTSO vs MMM
Side-by-side comparison of Cytosorbents Corporation (CTSO) and 3M Company (MMM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CTSO and MMM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MMM is the larger of the two at $87.46B, about 3851.0x CTSO ($22.7M).
- Over the past year, CTSO is down 60.2% and MMM is up 13.6% - MMM leads by 73.8 points.
- MMM has been more active in the news (14 items in the past 4 weeks vs 2 for CTSO).
- MMM has more recent analyst coverage (25 ratings vs 2 for CTSO).
- Company
- Cytosorbents Corporation
- 3M Company
- Price
- $0.40+1.65%
- $169.54-0.74%
- Market cap
- $22.7M
- $87.46B
- 1M return
- -4.01%
- +4.70%
- 1Y return
- -60.21%
- +13.59%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 2
- 14
- Recent ratings
- 2
- 25
Cytosorbents Corporation
Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of post-operative complications of cardiopulmonary bypass surgery, and maintaining or improving the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; and DrugSorb, a device to remove toxic chemicals from the blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is based in Monmouth Junction, New Jersey.
3M Company
3M Company develops, manufactures, and markets various products worldwide. It operates through four business segments: Safety and Industrial, Transportation and Electronics, Health Care, and Consumer. The Safety and Industrial segment offers personal safety products, industrial adhesives and tapes, abrasives, closure and masking systems, electrical markets, automotive aftermarket, and roofing granules to industrial, electrical, and safety markets. The Transportation and Electronics provides electronics, such as display materials and systems, electronic materials solutions; automotive and aerospace, and commercial solutions; advanced materials; and transportation safety products to transportation and electronic original equipment manufacturer customers. The Health Care segment offers medical and surgical supplies, skin health and infection prevention products, oral care, separation and purification sciences, health information systems, drug delivery systems, and food safety products to healthcare industry. The Consumer segment provides home improvement, home care, and consumer health care products, as well as stationery and office supplies to various consumers. This segment is also involved in the retail auto care business. It offers its products through various e-commerce and traditional wholesalers, retailers, jobbers, distributors, and dealers, as well as directly to users. 3M Company has a strategic collaboration with Merry Maids in residential cleaning sector; and collaborations with The Infectious Disease Research Institute and Duke Human Vaccine Institute to create a vaccine candidate with potential to provide protection against multiple variants of SARS-CoV-2. The company was founded in 1902 and is headquartered in St. Paul, Minnesota.
Latest CTSO
- CytoSorbents to Report Second Quarter 2026 Financial Results and Recent Business Highlights
- Cytosorbents Corporation filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing
- SEC Form DEFA14A filed by Cytosorbents Corporation
- SEC Form DEF 14A filed by Cytosorbents Corporation
- Cytosorbents Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th
- CytoSorbents to Present at the Life Sciences Forum on June 24, 2026 and Meet Virtually with Investors on June 30, 2026
- Chief Financial Officer Mariani Peter J bought $44,000 worth of shares (100,000 units at $0.44), increasing direct ownership by 19% to 638,113 units (SEC Form 4)
- Chief Executive Officer Chan Phillip P. bought $104,898 worth of shares (261,469 units at $0.40), increasing direct ownership by 18% to 1,744,432 units (SEC Form 4)
Latest MMM
- EVP, Chief Legal Off & Secret Rhodes Kevin H exercised 7,669 shares at a strike of $154.69 and sold $1,312,933 worth of shares (7,669 units at $171.20) (SEC Form 4)
- Group President Goralski Christian T Jr exercised 4,902 shares at a strike of $154.69 and sold $835,577 worth of shares (4,902 units at $170.46), decreasing direct ownership by 0.00% to 6,971 units (SEC Form 4)
- SEC Form 144 filed by 3M Company
- SEC Form 10-Q filed by 3M Company
- 3M Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- 3M Reports Second-Quarter 2026 Results; Increases Full-Year Guidance
- 3M upgraded by Analyst with a new price target
- 3M and Microsoft announce strategic partnership to advance AI data center infrastructure and enterprise transformation
- Scotch™ Brand launches Scotch Kids® Tape for young creators
- 3M Announces Upcoming Investor Event